Advances in Immuno-Oncology Therapeutics for Metastatic Triple-Negative Breast Cancer

Engage with this series of 4 focused ClinicalThought commentaries to gain expert insight on how to optimally integrate immunotherapy into the care of your patients with metastatic TNBC.

Share

Program Content

Activities

IO in TNBC: irAE Management
How I Manage Toxicities Associated with Immune Checkpoint Inhibition in My Patients with Metastatic TNBC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2020

Expires: March 15, 2021

IO for Metastatic TNBC
How I Am Using Immunotherapy in the Management of Metastatic TNBC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 02, 2020

Expires: April 01, 2021

IO for Early-Stage TNBC
Moving Immunotherapy Into Earlier Settings for Triple-Negative Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 17, 2020

Expires: April 16, 2021

Combination IO for mTNBC
Future Directions in Combination Immunotherapy Strategies for Metastatic Triple-Negative Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 27, 2020

Expires: April 26, 2021

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only